Methyl 2-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methylideneamino]acetate | 951403-91-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Methyl 2-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methylideneamino]acetate
• CAS: 951403-91-1
• 化学式: C₂₂H₂₂N₂O₄
• 分子量: 378.428
• InChiKey: BTXQWXBNJZFBSF-UHFFFAOYSA-N

物化性质

• 沸点：
  548.2±60.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  73.9
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Methyl 2-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methylideneamino]acetate 在 lithium hydroxide 、 sodium tetrahydroborate 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 8.0h， 生成 莫格列地
  参考文献：
  名称：

  Design and Synthesis of N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a Novel Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist with Efficacious Glucose and Lipid-Lowering Activities

  摘要：

  Muraglitazar/BMS-298585 (2) has been identified as a non-thiazolidinedione PPAR alpha/gamma dual agonist that shows potent activity in vitro at human PPAR alpha (EC50 = 320 nM) and PPAR gamma (EC50 = 110 nM). Compound 2 shows excellent efficacy for lowering glucose, insulin, triglycerides, and free fatty acids in genetically obese, severely diabetic db/db mice and has a favorable ADME profile. Compound 2 is currently in clinical development for the treatment of type 2 diabetes and dyslipidemia.

  DOI：

  10.1021/jm0496436
• 作为产物：
  描述：

  2-(5-甲基-2-苯基-1,3-恶唑-4-基)乙基甲烷磺酸酯 在 4 A molecular sieve 、 magnesium sulfate 、 potassium carbonate 、 三乙胺 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 36.0h， 生成 Methyl 2-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methylideneamino]acetate
  参考文献：
  名称：

  Design and Synthesis of N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a Novel Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist with Efficacious Glucose and Lipid-Lowering Activities

  摘要：

  Muraglitazar/BMS-298585 (2) has been identified as a non-thiazolidinedione PPAR alpha/gamma dual agonist that shows potent activity in vitro at human PPAR alpha (EC50 = 320 nM) and PPAR gamma (EC50 = 110 nM). Compound 2 shows excellent efficacy for lowering glucose, insulin, triglycerides, and free fatty acids in genetically obese, severely diabetic db/db mice and has a favorable ADME profile. Compound 2 is currently in clinical development for the treatment of type 2 diabetes and dyslipidemia.

  DOI：

  10.1021/jm0496436

文献信息

• [EN] PROCESS OF PREPARING SUBSTITUTED CARBAMATES AND INTERMEDIATES THEREOF<br/>[FR] PROCEDE DE PREPARATION DE CARBAMATES SUBSTITUES ET INTERMEDIAIRES DE CEUX-CI
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2005113521A1

  公开（公告）日：2005-12-01

  An improved process of preparing substituted carbamate derivatives, and crystalline forms thereof, useful for the treatment of dyslipidemia and diabetes, and intermediates thereof are provided.

  提供了一种改进的制备替代氨基甲酸酯衍生物及其结晶形式的过程，用于治疗血脂异常和糖尿病，以及其中间体。